Teva Gives OTCs “Major” Role In 2014 Outlook
This article was originally published in The Tan Sheet
The Israeli firm reassures investors that the business is stable and is moving forward with strategic plans after the abrupt exit of its CEO. Teva’s OTC business will be a key driver of those plans, says interim CEO Eyal Desheh.
You may also be interested in...
PGT Healthcare CEO Briain de Buitleir and COO Eli Shani say the joint venture will help Teva realize greater value for its localized OTCs and enable Procter & Gamble to expand its nutritional products portfolio.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.